[{"id":"714db3ca-404e-4222-9a0f-e2cca6ea14dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT07483567","created_at":"2026-03-28T01:36:25.975Z","updated_at":"2026-03-28T01:36:25.975Z","phase":"Phase 2","brief_title":"IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT07483567","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 03/30/2026","start_date":" 03/30/2026","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2026-03-19"},{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"778d6e97-aaea-4385-b9ac-14c267296d2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07474324","created_at":"2026-03-28T01:42:37.705Z","updated_at":"2026-03-28T01:42:37.705Z","phase":"Phase 2","brief_title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","source_id_and_acronym":"NCT07474324","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Aidixi (disitamab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2026-03-16"},{"id":"8429aef2-3578-430a-8f3c-fc5f753d6982","acronym":"","url":"https://clinicaltrials.gov/study/NCT07161453","created_at":"2025-09-13T08:46:03.641Z","updated_at":"2025-09-13T08:46:03.641Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","source_id_and_acronym":"NCT07161453","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-08"},{"id":"efd9f946-f015-462e-a89d-d7d3988373c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07149181","created_at":"2025-08-30T13:47:49.395Z","updated_at":"2025-08-30T13:47:49.395Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery","source_id_and_acronym":"NCT07149181","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/31/2025","start_date":" 08/31/2025","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-08-29"},{"id":"40eafc96-e8a8-4405-abf1-3e7824637479","acronym":"","url":"https://clinicaltrials.gov/study/NCT07132528","created_at":"2025-08-23T13:29:17.809Z","updated_at":"2025-08-23T13:29:17.809Z","phase":"Phase 4","brief_title":"Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","source_id_and_acronym":"NCT07132528","lead_sponsor":"Liaoning Cancer Hospital \u0026 Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 08/31/2025","start_date":" 08/31/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-08-20"},{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"722a2a86-9fad-4d71-874a-87f0351a5eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06925243","created_at":"2025-06-28T16:10:56.066Z","updated_at":"2025-06-28T16:10:56.066Z","phase":"Phase 3","brief_title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06925243","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 682","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-22"},{"id":"e42e13ac-a207-4481-8490-407dcba3be1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06939452","created_at":"2025-09-07T01:21:18.589Z","updated_at":"2025-09-07T01:21:18.589Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression","source_id_and_acronym":"NCT06939452","lead_sponsor":"Yongxu Jia","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/07/2023","start_date":" 06/07/2023","primary_txt":" Primary completion: 06/07/2025","primary_completion_date":" 06/07/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-04-22"},{"id":"488850a4-401a-418b-88e8-32f7b6c5f0dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038578","created_at":"2023-09-15T18:09:55.230Z","updated_at":"2025-02-25T13:41:43.311Z","phase":"Phase 2","brief_title":"A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer","source_id_and_acronym":"NCT06038578","lead_sponsor":"Toray Industries, Inc","biomarkers":" CAPRIN1","pipe":"","alterations":" ","tags":["CAPRIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • TRK-950"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-21"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"b94d3fe3-9040-4df9-8c37-231f34f9f98f","acronym":"POLESTAR","url":"https://clinicaltrials.gov/study/NCT05268510","created_at":"2022-03-07T18:53:55.391Z","updated_at":"2025-02-25T13:54:16.446Z","phase":"Phase 2","brief_title":"Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma","source_id_and_acronym":"NCT05268510 - POLESTAR","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" HER-2 • PD-L1 • CD8 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 08/27/2024","primary_completion_date":" 08/27/2024","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-20"},{"id":"3875d166-2701-445e-aa30-32ca8986f0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092518","created_at":"2021-01-18T15:14:06.092Z","updated_at":"2025-02-25T14:01:14.625Z","phase":"Phase 2","brief_title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","source_id_and_acronym":"NCT03092518","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mitomycin • Jelmyto (mitomycin urothelial gel)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/05/2017","start_date":" 06/05/2017","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-02-19"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"3641271b-5a0e-409d-997b-5bc0800249e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056024","created_at":"2023-09-28T15:10:33.953Z","updated_at":"2025-02-25T14:18:20.983Z","phase":"Phase 1","brief_title":"A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus","source_id_and_acronym":"NCT06056024","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 05/26/2027","primary_completion_date":" 05/26/2027","study_txt":" Completion: 05/26/2027","study_completion_date":" 05/26/2027","last_update_posted":"2025-02-18"},{"id":"91fb4f60-829a-4224-bfce-3668ff6fda2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04771520","created_at":"2021-02-25T15:52:21.802Z","updated_at":"2025-02-25T14:15:51.905Z","phase":"Phase 2","brief_title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT04771520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"a97f479a-477d-44f3-a5e0-9f9fc842a61b","acronym":"Keynote E70","url":"https://clinicaltrials.gov/study/NCT06116136","created_at":"2023-11-03T20:12:25.319Z","updated_at":"2025-02-25T14:42:27.915Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","source_id_and_acronym":"NCT06116136 - Keynote E70","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • S95029"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/31/2024","start_date":" 08/31/2024","primary_txt":" Primary completion: 06/10/2026","primary_completion_date":" 06/10/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-02-14"},{"id":"d1c6f091-2d7d-4e24-bd1c-40f7dd6031e6","acronym":"RATIONALE 305","url":"https://clinicaltrials.gov/study/NCT03777657","created_at":"2024-05-12T00:59:46.180Z","updated_at":"2025-02-25T14:40:05.546Z","phase":"Phase 3","brief_title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","source_id_and_acronym":"NCT03777657 - RATIONALE 305","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 997","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 08/27/2024","study_completion_date":" 08/27/2024","last_update_posted":"2025-02-14"},{"id":"bcfa1353-7be6-4150-b82c-bf13212f8a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836584","created_at":"2023-05-01T14:03:52.795Z","updated_at":"2025-02-25T15:13:28.038Z","phase":"Phase 2","brief_title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT05836584","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-13"},{"id":"c806a099-ac30-4f24-bc10-a04a25d2bf23","acronym":"GEMINI-Gastric","url":"https://clinicaltrials.gov/study/NCT05702229","created_at":"2023-11-09T18:13:01.598Z","updated_at":"2025-02-25T15:13:18.164Z","phase":"Phase 2","brief_title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT05702229 - GEMINI-Gastric","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 01/16/2023","start_date":" 01/16/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/28/2027","study_completion_date":" 01/28/2027","last_update_posted":"2025-02-13"},{"id":"e5e3ad81-9df9-4560-a791-5e9b3953d9ad","acronym":"KYM901","url":"https://clinicaltrials.gov/study/NCT04805307","created_at":"2021-03-18T11:52:24.597Z","updated_at":"2025-02-25T15:19:03.220Z","phase":"Phase 1","brief_title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","source_id_and_acronym":"NCT04805307 - KYM901","lead_sponsor":"Keymed Biosciences Co.Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sonesitatug vedotin (AZD0901)"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 04/05/2024","study_completion_date":" 04/05/2024","last_update_posted":"2025-02-12"},{"id":"3a138d15-6bca-4eff-8361-765e025c0dc8","acronym":"FORTITUDE-101","url":"https://clinicaltrials.gov/study/NCT05052801","created_at":"2021-09-22T11:53:35.151Z","updated_at":"2025-02-25T16:38:37.071Z","phase":"Phase 3","brief_title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","source_id_and_acronym":"NCT05052801 - FORTITUDE-101","lead_sponsor":"Amgen","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 overexpression • FGFR2b overexpression","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 overexpression • FGFR2b overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • bemarituzumab (AMG 552)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 547","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 08/18/2025","study_completion_date":" 08/18/2025","last_update_posted":"2025-02-07"},{"id":"b85874df-7e06-4405-a134-b832b090826f","acronym":"RCTS","url":"https://clinicaltrials.gov/study/NCT05586061","created_at":"2022-10-19T13:56:28.812Z","updated_at":"2025-02-25T16:33:09.486Z","phase":"Phase 2","brief_title":"First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer","source_id_and_acronym":"NCT05586061 - RCTS","lead_sponsor":"Qilu Hospital of Shandong University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Aidixi (disitamab vedotin) • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 12/29/2024","primary_completion_date":" 12/29/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"60529635-af59-4ddd-9192-b5ec25989186","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661150","created_at":"2021-01-19T20:42:55.568Z","updated_at":"2025-02-25T16:38:08.739Z","phase":"Phase 2","brief_title":"A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction","source_id_and_acronym":"NCT04661150","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/12/2021","start_date":" 03/12/2021","primary_txt":" Primary completion: 05/08/2023","primary_completion_date":" 05/08/2023","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-06"}]